Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis

Gil Yosipovitch; Marjolein de Bruin-Weller; Marni Wiseman; Jesper Elberling; Jan Gutermuth; Evangeline Pierce; Sonia Montmayeur; Fan Emily Yang; Yuxin Ding; Laia Bardolet; Sarah Chisolm

doi:10.1093/ced/llae541

Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis

Gil Yosipovitch^*, Marjolein de Bruin-Weller, Marni Wiseman, Jesper Elberling, Jan Gutermuth, Evangeline Pierce, Sonia Montmayeur, Fan Emily Yang, Yuxin Ding, Laia Bardolet, Sarah Chisolm

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Abstract

Pruritus is a hallmark symptom of atopic dermatitis (AD) and is known to worsen patients' health-related quality of life. Lebrikizumab is a high-affinity monoclonal antibody which binds IL-13, a dominant cytokine implicated in AD. This study includes data from two Phase 3 randomized controlled trials assessing the efficacy and safety of lebrikizumab in patients with moderate-to-severe AD, ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). We report a post-hoc analysis to quantify the effect of lebrikizumab vs placebo on the Dermatology Life Quality Index (DLQI) mediated indirectly through its effect on patient-reported outcomes itch and itch interference on sleep. Approximately two-thirds of the improvement in DLQI experienced by lebrikizumab-treated patients vs placebo-treated patients at Week 16 was mediated by improvement in itch and the interference of itch on sleep.

Originalsprog	Engelsk
Tidsskrift	Clinical and Experimental Dermatology
Antal sider	5
ISSN	0307-6938
DOI	https://doi.org/10.1093/ced/llae541
Status	E-pub ahead of print - 2025

Bibliografisk note

Adgang til dokumentet

10.1093/ced/llae541Licens: CC BY-NC

Citationsformater

Yosipovitch, G., de Bruin-Weller, M., Wiseman, M., Elberling, J., Gutermuth, J., Pierce, E., Montmayeur, S., Yang, F. E., Ding, Y., Bardolet, L., & Chisolm, S. (2025). Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis. Clinical and Experimental Dermatology. Advance online publication. https://doi.org/10.1093/ced/llae541

Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis. / Yosipovitch, Gil; de Bruin-Weller, Marjolein; Wiseman, Marni et al.
I: Clinical and Experimental Dermatology, 2025.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Yosipovitch, G, de Bruin-Weller, M, Wiseman, M, Elberling, J, Gutermuth, J, Pierce, E, Montmayeur, S, Yang, FE, Ding, Y, Bardolet, L & Chisolm, S 2025, 'Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis', Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae541

Yosipovitch G, de Bruin-Weller M, Wiseman M, Elberling J, Gutermuth J, Pierce E et al. Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis. Clinical and Experimental Dermatology. 2025. Epub 2025. doi: 10.1093/ced/llae541

@article{415da2acef1a4d9996e6cf19211636ed,

title = "Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis",

abstract = "Pruritus is a hallmark symptom of atopic dermatitis (AD) and is known to worsen patients' health-related quality of life. Lebrikizumab is a high-affinity monoclonal antibody which binds IL-13, a dominant cytokine implicated in AD. This study includes data from two Phase 3 randomized controlled trials assessing the efficacy and safety of lebrikizumab in patients with moderate-to-severe AD, ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). We report a post-hoc analysis to quantify the effect of lebrikizumab vs placebo on the Dermatology Life Quality Index (DLQI) mediated indirectly through its effect on patient-reported outcomes itch and itch interference on sleep. Approximately two-thirds of the improvement in DLQI experienced by lebrikizumab-treated patients vs placebo-treated patients at Week 16 was mediated by improvement in itch and the interference of itch on sleep.",

author = "Gil Yosipovitch and {de Bruin-Weller}, Marjolein and Marni Wiseman and Jesper Elberling and Jan Gutermuth and Evangeline Pierce and Sonia Montmayeur and Yang, {Fan Emily} and Yuxin Ding and Laia Bardolet and Sarah Chisolm",

note = "{\textcopyright} The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists.",

year = "2025",

doi = "10.1093/ced/llae541",

language = "English",

journal = "Clinical and Experimental Dermatology",

issn = "0307-6938",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep

T2 - Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis

AU - Yosipovitch, Gil

AU - de Bruin-Weller, Marjolein

AU - Wiseman, Marni

AU - Elberling, Jesper

AU - Gutermuth, Jan

AU - Pierce, Evangeline

AU - Montmayeur, Sonia

AU - Yang, Fan Emily

AU - Ding, Yuxin

AU - Bardolet, Laia

AU - Chisolm, Sarah

PY - 2025

Y1 - 2025

N2 - Pruritus is a hallmark symptom of atopic dermatitis (AD) and is known to worsen patients' health-related quality of life. Lebrikizumab is a high-affinity monoclonal antibody which binds IL-13, a dominant cytokine implicated in AD. This study includes data from two Phase 3 randomized controlled trials assessing the efficacy and safety of lebrikizumab in patients with moderate-to-severe AD, ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). We report a post-hoc analysis to quantify the effect of lebrikizumab vs placebo on the Dermatology Life Quality Index (DLQI) mediated indirectly through its effect on patient-reported outcomes itch and itch interference on sleep. Approximately two-thirds of the improvement in DLQI experienced by lebrikizumab-treated patients vs placebo-treated patients at Week 16 was mediated by improvement in itch and the interference of itch on sleep.

AB - Pruritus is a hallmark symptom of atopic dermatitis (AD) and is known to worsen patients' health-related quality of life. Lebrikizumab is a high-affinity monoclonal antibody which binds IL-13, a dominant cytokine implicated in AD. This study includes data from two Phase 3 randomized controlled trials assessing the efficacy and safety of lebrikizumab in patients with moderate-to-severe AD, ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). We report a post-hoc analysis to quantify the effect of lebrikizumab vs placebo on the Dermatology Life Quality Index (DLQI) mediated indirectly through its effect on patient-reported outcomes itch and itch interference on sleep. Approximately two-thirds of the improvement in DLQI experienced by lebrikizumab-treated patients vs placebo-treated patients at Week 16 was mediated by improvement in itch and the interference of itch on sleep.

U2 - 10.1093/ced/llae541

DO - 10.1093/ced/llae541

M3 - Journal article

C2 - 39680511

SN - 0307-6938

JO - Clinical and Experimental Dermatology

JF - Clinical and Experimental Dermatology

ER -